We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

DOCICAR: Cardiac Dysfunction in Cirrhosis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00250315
First Posted: November 8, 2005
Last Update Posted: November 1, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hvidovre University Hospital
  Purpose
Patients with cirrhosis have a altered cardiac response to stress. This study evaluate the cardiac response by MRI during dobutamine stress. Hypothesis: impared increase in cardiac output, cardiac index, ejection fraction.

Condition Intervention Phase
Cirrhosis Cirrhotic Cardiomyopathy Drug: Dobutamine Phase 3

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Cardiac Dysfunction in Cirrhosis: Cirrhotic Cardiomyopathy Evaluated by Dobutamin MRI.

Resource links provided by NLM:


Further study details as provided by Hvidovre University Hospital:

Study Start Date: November 2005
Study Completion Date: October 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Non alkoholic cirrhosis

Exclusion Criteria:

  • Coma hepaticum
  • Primary cardiac diseases
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00250315


Locations
Denmark
Hvidovre University Hospital
Copenhagen, Hvidovre, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital
Investigators
Study Director: Søren Møller, DrMsci, MD Hvidovre University Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00250315     History of Changes
Other Study ID Numbers: (KF) 01 270675
First Submitted: November 4, 2005
First Posted: November 8, 2005
Last Update Posted: November 1, 2007
Last Verified: October 2007

Additional relevant MeSH terms:
Fibrosis
Liver Cirrhosis
Cardiomyopathies
Pathologic Processes
Liver Diseases
Digestive System Diseases
Heart Diseases
Cardiovascular Diseases
Dobutamine
Cardiotonic Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents